Search

everythinglearnresearchcommunity

for

Search:↓

Melatonin at a 0.0033% concentration shows results for hair loss when used topically. A user is discussing how to replicate this by adding 2mg of Melatonin to 60ml of Minoxidil solution.

Oral minoxidil can lead to increased body hair growth, especially in areas where hair already exists, but results vary by individual. Some users report noticeable changes within a few months, while others see minimal impact; concerns about excessive hair growth are common, but many prioritize hairline improvement over body hair concerns.

The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.

Counterfeit minoxidil can be identified by inconsistencies in bottle fill levels, label details, and smell compared to genuine products. Genuine minoxidil has a specific alcohol-based smell and consistency, while counterfeit versions may smell musky and feel greasy.

The user left their 2.5 mg pills at home and is considering using 5% topical minoxidil as a substitute. They also inquire about where to obtain over-the-counter minoxidil pills.

The user is considering switching from a topical minoxidil and finasteride solution to oral minoxidil to improve hair growth, while maintaining oral finasteride. They are concerned about potential shedding and whether they can maintain any new growth.

Taking 2.5mg oral Minoxidil daily can increase body hair, with users reporting thicker and longer hair, including on eyebrows and eyelashes. Some users suggest starting with a lower dose to manage unwanted hair growth.

A user is considering switching from regular 5% minoxidil foam to a compounded 5% minoxidil spray with added caffeine, melatonin, and tretinoin for easier application and potentially better results. Another user mentions that tretinoin can enhance minoxidil's effectiveness by converting it to its active form.

Oral minoxidil is considered more convenient and effective than topical or sublingual forms, with users reporting positive results and minimal side effects. Some users experience side effects with oral minoxidil and opt for sublingual or topical methods instead.

A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.

A user has been using minoxidil without noticing improvements and is considering adding tretinoin gel to their regimen before trying RU58841. They seek advice on how to mix and apply tretinoin with minoxidil, including concentration and application frequency.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

An experiment to determine the effectiveness of Pyrilutamide in reducing hair loss, using a regimen of Minoxidil and Finasteride, with promising results. The conversation also suggests comparing this to RU58841 as an alternative.

The user experienced sensitivity and side effects from finasteride and Saw Palmetto, leading to swollen and sensitive breasts, and decided to stop finasteride after two weeks. They are now trying Saw Palmetto, Biotin, and Ashwagandha, while others in the conversation discuss their own experiences with hair loss treatments like minoxidil and finasteride.

The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The conversation discusses using stemoxydine for hair loss, with OP considering using 1.5 ml daily despite the recommended 6 ml. Some users doubt its effectiveness, while others report positive experiences using similar amounts.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.

The user has been using 5% minoxidil once daily and microneedling with a 1.5 mm dermaroller weekly for three months, considering increasing minoxidil usage but avoiding finasteride due to libido concerns. Another person suggests considering other treatments like RU58841, alfatradiol, topical finasteride, clascoterone, or saw palmetto since not using a DHT blocker could be less effective.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

A 19-year-old is experiencing hereditary hair thinning and is considering switching from topical to oral minoxidil due to convenience and starting finasteride at a low dose to minimize side effects. A suggestion was made to start with 0.25 mg of finasteride daily and gradually increase to 0.5 mg, while oral minoxidil requires a prescription.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The user switched from 5% to 2% minoxidil due to a purchasing mistake and is concerned about potential hair loss or shedding. Suggestions include using 2% minoxidil more frequently or in larger amounts to compensate.

The user plans to lower their oral minoxidil dose from 5 mg to 2.5 mg to reduce side effects like puffiness and hypertrichosis, while also using finasteride and accutane. They are considering caffeine serums for puffiness and discussing dietary changes or switching to topical minoxidil to address bloating.

A 20-year-old male switched from MorrF5 to Zeelab’s MinoxilF, both containing minoxidil 5% and finasteride 0.1%, and is experiencing unexpected hair shedding. He is seeking guidance on whether the shedding is due to the brand change or if it's a normal reaction.

Salicylic Acid shampoo may hinder topical minoxidil but not oral minoxidil, which works through the liver. The user plans to continue using oral minoxidil and is concerned about the shampoo's effect on it.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.